These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33803472)

  • 1. Plumbagin, a Biomolecule with (Anti)Osteoclastic Properties.
    Sultanli S; Ghumnani S; Ashma R; Kubatzky KF
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IκBα.
    Ma Z; Yu R; Zhao J; Sun L; Jian L; Li C; Liu X
    Inflamm Res; 2019 Feb; 68(2):157-166. PubMed ID: 30604211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.
    Gong W; Dou H; Liu X; Sun L; Hou Y
    Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
    Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
    Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
    Valverde P; Tu Q; Chen J
    J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhinacanthin C Inhibits Osteoclast Differentiation and Bone Resorption: Roles of TRAF6/TAK1/MAPKs/NF-κB/NFATc1 Signaling.
    Tomomura M; Suzuki R; Shirataki Y; Sakagami H; Tamura N; Tomomura A
    PLoS One; 2015; 10(6):e0130174. PubMed ID: 26083531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-phycocyanin attenuates RANKL-induced osteoclastogenesis and bone resorption in vitro through inhibiting ROS levels, NFATc1 and NF-κB activation.
    AlQranei MS; Aljohani H; Majumdar S; Senbanjo LT; Chellaiah MA
    Sci Rep; 2020 Feb; 10(1):2513. PubMed ID: 32054921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diarylheptanoid from Curcuma comosa Roxb. suppresses RANKL-induced osteoclast differentiation by decreasing NFATc1 and c-Fos expression via MAPK pathway.
    Chawalitpong S; Sornkaew N; Suksamrarn A; Palaga T
    Eur J Pharmacol; 2016 Oct; 788():351-359. PubMed ID: 27523282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo.
    Yonezawa T; Hasegawa S; Asai M; Ninomiya T; Sasaki T; Cha BY; Teruya T; Ozawa H; Yagasaki K; Nagai K; Woo JT
    Eur J Pharmacol; 2011 Jan; 650(2-3):511-8. PubMed ID: 21047508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microtubule actin crosslinking factor 1 (MACF1) knockdown inhibits RANKL-induced osteoclastogenesis via Akt/GSK3β/NFATc1 signalling pathway.
    Lin X; Xiao Y; Chen Z; Ma J; Qiu W; Zhang K; Xu F; Dang K; Qian A
    Mol Cell Endocrinol; 2019 Aug; 494():110494. PubMed ID: 31260729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms involved in enhancement of osteoclast formation by activin-A.
    Kajita T; Ariyoshi W; Okinaga T; Mitsugi S; Tominaga K; Nishihara T
    J Cell Biochem; 2018 Aug; 119(8):6974-6985. PubMed ID: 29737562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achyranthes bidentata polysaccharide suppresses osteoclastogenesis and bone resorption via inhibiting RANKL signaling.
    Song D; Cao Z; Huang S; Tickner J; Li N; Qiu H; Chen X; Wang C; Chen K; Sun Y; Dong S; Xu J
    J Cell Biochem; 2018 Jun; 119(6):4826-4835. PubMed ID: 29345352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of cytokines in inflammatory bone loss.
    Souza PP; Lerner UH
    Immunol Invest; 2013; 42(7):555-622. PubMed ID: 24004059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
    Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
    J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ganomycin I from Ganoderma lucidum attenuates RANKL-mediated osteoclastogenesis by inhibiting MAPKs and NFATc1.
    Tran PT; Dat NT; Dang NH; Van Cuong P; Lee S; Hwangbo C; Van Minh C; Lee JH
    Phytomedicine; 2019 Mar; 55():1-8. PubMed ID: 30668419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockdown of TRPV4 suppresses osteoclast differentiation and osteoporosis by inhibiting autophagy through Ca
    Cao B; Dai X; Wang W
    J Cell Physiol; 2019 May; 234(5):6831-6841. PubMed ID: 30387123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcineurin/NFAT signaling pathway mediates titanium particle‑induced inflammation and osteoclast formation by inhibiting RANKL and M‑CSF in vitro.
    Zhang Y; Jiang P; Li W; Liu X; Lu Y; Huang Z; Song K
    Mol Med Rep; 2017 Dec; 16(6):8223-8230. PubMed ID: 28990090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oleanolic acid acetate inhibits osteoclast differentiation by downregulating PLCγ2-Ca(2+)-NFATc1 signaling, and suppresses bone loss in mice.
    Kim JY; Cheon YH; Oh HM; Rho MC; Erkhembaatar M; Kim MS; Lee CH; Kim JJ; Choi MK; Yoon KH; Lee MS; Oh J
    Bone; 2014 Mar; 60():104-11. PubMed ID: 24361669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.